Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205

T. Li, P. J. Christos, J. A. Sparano, D. L. Hershman, S. Hoschander, K. O'Brien, J. J. Wright, L. T. Vahdat

Research output: Contribution to journalArticle

28 Scopus citations

Fingerprint Dive into the research topics of 'Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205'. Together they form a unique fingerprint.

Medicine & Life Sciences